Group 1 - The company, Yaoshi Technology, positions itself as a global chemical technology innovation platform in the pharmaceutical R&D and manufacturing sector [1] - The company leverages its advantages in molecular building block design and synthesis technology, as well as green low-carbon chemical technology, to explore applications across multiple fields [1] - The company aims to extend its technological capabilities from chemical drugs to new materials, new energy, and green agriculture, thereby building a cross-industry technology empowerment system [1] Group 2 - The company commits to timely information disclosure in accordance with legal regulations if there are significant business developments that meet disclosure standards [1]

Core Viewpoint - The company is focusing on the development opportunities in the oligonucleotide drug field and has established a specialized team to enhance its capabilities in this area [1] Group 1 - The company has designed a diverse range of molecular building blocks, including nucleotides, phosphoramidites, and delivery technologies, with over 500 product types currently available [1] - In the first half of this year, the company integrated internal resources to establish a professional peptide and oligonucleotide team (PTCoE) [1] - The company is accelerating its capabilities in oligonucleotide synthesis, chemical modification, conjugation, process development, and analysis [1] Group 2 - The company will continue to closely monitor industry technology development trends and will timely advance relevant layouts [1]

Core Viewpoint - The company has established an advanced technology platform and product library in the field of non-natural amino acids, with a commitment to continuous technological innovation to support global customers in drug development [1] Summary by Categories Technology and Product Development - The company has developed tens of thousands of non-natural amino acids, with over 10,000 catalog products available [1] - More than 1,300 products are in stock, and over 100 products have kilogram-level production experience [1] - The company can supply over 20 products at the hundred-kilogram level [1] Commitment to Innovation - The company is dedicated to providing high-quality non-natural amino acid products and related technical services to assist in innovative drug research and development [1]

南京药石科技股份有限公司 证券代码：300725 证券简称：药石科技 公告编号：2025-095 关于控股股东、实际控制人及其一致行动人权益变动触及1%整数倍的公告 公司股东南京诺维科思创业投资合伙企业（有限合伙）保证向本公司提供的信息内 容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 南京药石科技股份有限公司（以下简称"公司"）于2025年7月10日披露了《关于 公司股东减持股份的预披露公告》（公告编号：2025-044）。公司员工持股平台南京诺 维科思创业投资合伙企业（有限合伙）（以下简称"诺维科思"）计划在本减持计划预 披露公告之日起十五个交易日后的三个月内（窗口期不减持），以集中竞价、大宗交易 方式减持其持有的全部公司股份。其中，通过集中竞价交易方式减持的，在任意连续90 个自然日内减持股份数量不超过公司股份总数的1.00%；通过大宗交易方式减持的，在 任意连续90个自然日内减持股份数量不超过公司股份总数的2.00%（减持期间如公司有 送股、资本公积金转增股本等导致持股数量变化，则减持数量进行相应调整）。 2025年9月26 ...

证券代码：300725 证券简称：药石科技 公告编号：2025-094 南京药石科技股份有限公司 关于药石转债摘牌的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、可转债赎回日：2025 年 9 月 18 日 2、投资者赎回款到账日：2025 年 9 月 25 日 3、可转债摘牌日：2025 年 9 月 26 日 4、摘牌原因：存续期内可转债全部赎回 一、可转换公司债券基本情况 1、本次发行的可转换公司债券的初始转股价格 92.98 元/股。 2、2022 年 5 月 19 日召开的公司 2021 年度股东大会，审议通过了《关于回 购注销部分激励对象已获授但尚未解除限售的限制性股票及调整回购价格的议 案》：同意董事会对 1 名激励对象已获授但尚未解除限售的 41,600 股限制性股 票进行回购注销。该部分限制性股票回购注销事宜已于 2022 年 6 月 1 日办理完 成，公司股份总数由 199,699,696 股变更为 199,658,096 股。由于本次回购注销限 制性股票数量较少，药石转债的转股价格未进行调整，仍为 92.98 元/股 ...

证券代码：300725 证券简称：药石科技 公告编号：2025-093 南京药石科技股份有限公司 关于药石转债赎回结果的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、可转换公司债券基本情况 （一）可转债发行情况 经中国证券监督管理委员会《关于同意南京药石科技股份有限公司向不特 定对象发行可转换公司债券注册的批复》（证监许可[2022]622 号）同意，公司 于 2022 年 4 月 20 日向不特定对象发行可转换公司债券 1150 万张，发行价格为 每张面值 100 元人民币，按面值发行，募集资金共计人民币 1,150,000,000.00 元。 （二）可转债上市情况 经深圳证券交易所同意，公司本次可转换公司债券于 2022 年 5 月 18 日起 在深圳证券交易所挂牌交易，债券代码为"123145"，债券简称"药石转债"。 （三）可转债转股期限 根据《募集说明书》的规定，本次发行的可转债转股期自可转债发行结束 之日起满六个月后的第一个交易日（2022 年 10 月 26 日）起至可转债到期日（2028 年 4 月 19 日）止。 （四）可转债转股 ...

Core Viewpoint - GenFleet Therapeutics successfully listed on the Hong Kong Stock Exchange on September 19, 2025, marking a significant milestone in its development and showcasing its innovative strength and growth potential [1][3]. Company Overview - GenFleet Therapeutics is the first new drug company in the 18A sector to have a listed product and authorized revenue during its IPO phase. Its product, Fluorazepine, is the first KRAS G12C inhibitor approved in China and the third globally [3][7]. - The company has completed multiple licensing transactions with domestic and international listed companies, including Innovent Biologics and Verastem Oncology, since 2021, generating authorized revenue [3][4]. Product Pipeline - GenFleet's product pipeline includes several original products that are leading in development speed both domestically and internationally. Fluorazepine received priority review qualification for domestic listing after six years of development [4]. - The company is advancing GFH375, an oral KRAS G12D inhibitor, which is in the first tier of development for treating pancreatic cancer and non-small cell lung cancer (NSCLC) [4]. - The pipeline also features GFH276, a pan-RAS inhibitor, which has entered Phase I/II clinical trials in China, positioning it among the leading candidates in the domestic market [4]. Innovative Therapies - GenFleet has introduced multiple globally innovative dual-target therapies, addressing significant clinical needs in markets such as pancreatic cancer and NSCLC. The KROCUS study presents the first global KRAS+EGFR first-line treatment for NSCLC [5]. - GFS202A is the first clinical-stage dual antibody therapy targeting GDF15/IL-6 for cachexia, with potential applications in chronic diseases like heart failure and chronic kidney disease [5]. - The FAScon platform represents a novel antibody-drug conjugate (ADC) approach, combining functional antibodies with targeted drug delivery, aiming to revolutionize traditional ADC development [5]. Collaboration and Support - PharmaBlock Technology plays a crucial role in supporting GenFleet's core pipeline through its comprehensive small molecule drug development services, including rapid synthesis of preclinical compounds and customized synthesis for clinical production [6]. - The collaboration emphasizes sustainable development through low-carbon production technologies and green chemistry practices, enhancing production efficiency while minimizing environmental impact [6]. Recognition and Achievements - GenFleet has received several accolades, including the national-level "Little Giant" designation and recognition as a high-tech enterprise, reflecting its innovative capabilities and growth trajectory [8]. - The company has established a robust commercial cooperation network, engaging in strategic licensing agreements and global clinical collaborations with various domestic and international firms [8].

Group 1 - Fuchun Dyeing and Weaving's controlling shareholders plan to reduce their holdings by a total of 1% of the company's shares, amounting to a maximum of 194.07 million shares [1] - Yaoshi Technology's shareholder plans to reduce holdings by up to 1% of the company's shares, totaling 232.96 million shares [1][2] - Fucai Technology's shareholder plans to transfer 170 million shares, representing 2.0038% of the company's total shares [3] Group 2 - Xiangxia Precision plans to invest 30 million yuan in a joint investment fund, representing 35.09% of the total subscription amount [4] - Anhui Heli intends to acquire 51% of Jianghuai Heavy Industry for 274 million yuan, which will be included in the company's consolidated financial statements [5] - Jida Zhengyuan's shareholder plans to reduce holdings by up to 3% of the company's shares, totaling 565.2 million shares [6] Group 3 - Hanyu Group plans to invest 10 million yuan in the Tianwei Fund, representing 45.43% of the total investment [7] - Tianshun Co. received a government subsidy of 6.375 million yuan, accounting for 71.49% of the company's latest audited net profit [8] - Hongfuhan's vice chairman plans to reduce holdings by up to 0.87% of the company's shares, totaling 77.63 million shares [9] Group 4 - Yunda Co. reported August express service revenue of 4.119 billion yuan, a year-on-year increase of 5.16% [10] - Feile Audio announced no plans to enter the lithography machine field [11] - Xidamen's controlling shareholder plans to reduce holdings by up to 15.7 million shares, representing 0.0821% of the company's total shares [12] Group 5 - Jian Sheng Group plans to invest in a new project in Vietnam with a total investment of 180 million yuan [13] - Yunnan Tourism's cooperation with Zhejiang Humanoid Robot Innovation Center is still in the early stages [14] - Fengcai Technology's shareholder plans to reduce holdings by up to 3% of the company's shares, totaling 341.76 million shares [16] Group 6 - Jinfat Technology has a penetration holding ratio of 0.32% in Yushu Technology [18][19] - Nanjing Public Utility terminated the cash acquisition of 68% of Yiguang Technology due to failure to reach an agreement [20] - Peking University Medicine plans to donate 3 million yuan to the Capital Medical University Education Foundation [21] Group 7 - Qin'an Co. is negotiating to purchase equity in Yigao Optoelectronics for cash [22] - Jinxin Co.'s major shareholder plans to reduce holdings by up to 1% of the company's shares, totaling 662.15 million shares [23] - Capital Online's two shareholders plan to transfer a total of 5.02% of the company's shares, amounting to 25.2076 million shares [24][25]

Summary of Key Points Core Viewpoint - On September 19, 2025, Yaoshi Technology executed a block trade of 163,000 shares at a price of 37.4 yuan, which represented a discount of 10.01% compared to the market closing price of 41.56 yuan [1]. Group 1: Trade Details - The total transaction amount for the block trade was 609.62 thousand yuan, accounting for 0.87% of the total trading volume on that day [1]. - The shares were traded at a price of 37.4 yuan, with a total volume of 16.3 million shares [1]. - The block trade involved multiple transactions, with the largest individual transaction being 5.5 million shares at the same price of 37.4 yuan [2]. Group 2: Buyer and Seller Information - The buyer for the transactions was identified as an institutional investor, specifically from Huatai Securities [2]. - The seller was also associated with Huatai Securities, indicating a potential internal transaction within the firm [2].

Market Overview - On September 19, the medical services sector declined by 0.8%, with Yaoshi Technology leading the drop [1] - The Shanghai Composite Index closed at 3820.09, down 0.3%, while the Shenzhen Component Index closed at 13070.86, down 0.04% [1] Stock Performance - Key stocks in the medical services sector experienced significant declines, with Yaoshi Technology falling by 4.79% to a closing price of 41.56 [1] - Other notable declines included Zenggansi (-4.72%), Meidixi (-4.47%), and Zhaoyan New Drug (-4.43%) [1] - The trading volume for Yaoshi Technology was 163,500 shares, with a transaction value of 6.91 billion yuan [1] Capital Flow - The medical services sector saw a net outflow of 1.777 billion yuan from institutional investors, while retail investors contributed a net inflow of 1.592 billion yuan [3] - Notable stocks with significant capital flow included Yingkang Life, which had a net inflow of 24.85 million yuan from institutional investors [3] - New Mileage experienced a net inflow of 16.46 million yuan from retail investors, despite a net outflow from institutional and speculative investors [3]